Lancet Respir Med by Muthuri, Stella G et al.
Effectiveness of neuraminidase inhibitors in reducing mortality 
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virus infection: a meta-analysis of individual participant data
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Summary
Background—Neuraminidase inhibitors were widely used during the 2009–10 influenza A 
H1N1 pandemic, but evidence for their effectiveness in reducing mortality is uncertain. We did a 
meta-analysis of individual participant data to investigate the association between use of 
neuraminidase inhibitors and mortality in patients admitted to hospital with pandemic influenza A 
H1N1pdm09 virus infection.
Methods—We assembled data for patients (all ages) admitted to hospital worldwide with 
laboratory confirmed or clinically diagnosed pandemic influenza A H1N1pdm09 virus infection. 
We identified potential data contributors from an earlier systematic review of reported studies 
addressing the same research question. In our systematic review, eligible studies were done 
between March 1, 2009 (Mexico), or April 1, 2009 (rest of the world), until the WHO declaration 
of the end of the pandemic (Aug 10, 2010); however, we continued to receive data up to March 14, 
2011, from ongoing studies. We did a meta-analysis of individual participant data to assess the 
association between neuraminidase inhibitor treatment and mortality (primary outcome), adjusting 
for both treatment propensity and potential confounders, using generalised linear mixed 
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modelling. We assessed the association with time to treatment using time-dependent Cox 
regression shared frailty modelling.
Findings—We included data for 29 234 patients from 78 studies of patients admitted to hospital 
between Jan 2, 2009, and March 14, 2011. Compared with no treatment, neuraminidase inhibitor 
treatment (irrespective of timing) was associated with a reduction in mortality risk (adjusted odds 
ratio [OR] 0·81; 95% CI 0·70–0·93; p=0·0024). Compared with later treatment, early treatment 
(within 2 days of symptom onset) was associated with a reduction in mortality risk (adjusted OR 
0·48; 95% CI 0·41–0·56; p<0·0001). Early treatment versus no treatment was also associated with 
a reduction in mortality (adjusted OR 0·50; 95% CI 0·37–0·67; p<0·0001). These associations with 
reduced mortality risk were less pronounced and not significant in children. There was an increase 
in the mortality hazard rate with each day’s delay in initiation of treatment up to day 5 as 
compared with treatment initiated within 2 days of symptom onset (adjusted hazard ratio [HR 
1·23] [95% CI 1·18–1·28]; p<0·0001 for the increasing HR with each day’s delay).
Interpretation—We advocate early instigation of neuraminidase inhibitor treatment in adults 
admitted to hospital with suspected or proven influenza infection.
Funding—F Hoffmann-La Roche.
Introduction
The neuraminidase inhibitors, oral oseltamivir and inhaled zanamivir, were the predominant 
medical countermeasure available from emergence of the influenza A H1N1pdm09 virus in 
early 2009, until the first release of monovalent H1N1 vaccines in October, 2009. 
Prescribing data from seven countries (Australia, Canada, France, Germany, Japan, UK, 
USA) suggest at least 18·3 million individuals received oseltamivir between May 1, 2009, 
and Dec 31, 2009.1 Country-specific policies for use of neuraminidase inhibitors during the 
2009–10 pandemic varied from no use, to targeted use in at-risk patients (most countries), to 
treatment of all patients with clinical illness (UK). Most use of neuraminidase inhibitors 
worldwide was in the form of oseltamivir—eg, 97·5% of neuraminidase inhibitors used in 
the USA.2
There is little prepandemic evidence pertaining to the effectiveness of neuraminidase 
inhibitors in reducing mortality in patients admitted to hospital with influenza; most 
evidence comes from observational studies of treatment of seasonal influenza, often in 
highly specific groups of patients.3-9 Thus, in 2009–10, neuraminidase inhibitors were used 
on the basis of rational deduction that they would reduce mortality due to influenza A 
H1N1pdm09 virus infection rather than on strong pre-existing evidence, although data from 
treatment of human influenza A H5N1 cases suggested this reduction in mortality might be 
possible.10,11 Japanese clinicians used neuraminidase inhibitors widely to treat all people 
presenting with clinical influenza in 2009–10 and recorded the lowest pandemic mortality 
rate of any developed country.12-14 Although a similar treat-all policy existed in the UK in 
2009, uptake of neuraminidase inhibitors in patients admitted to hospital with influenza A 
H1N1pdm09 was low.15
Two systematic reviews and meta-analyses have examined the effectiveness of 
neuraminidase inhibitors in reducing mortality due to influenza. Both suggest substantial 
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reductions in mortality by two-thirds to three-quarters compared with no treatment.16,17 
However, limitations are apparent, such as the heterogeneity of studies included and 
inadequate adjustment for potential confounding. Importantly, neither was able to adjust for 
the likelihood of a patient receiving antiviral treatment (propensity)—a crucial consideration 
when antiviral drugs might have been prioritised towards the sickest patients—and neither 
was able to use a pooled analysis approach with individual participant data.18
Methods
Study design and identification of datasets
The Post-pandemic Review of anti-Influenza Drug Effectiveness (PRIDE) research 
consortium was set up in October, 2011, and is coordinated by the Health Protection and 
Influenza Research Group at the University of Nottingham, Nottingham, UK. The aim ofthe 
collaboration is to do individual participant data meta-analyses of the effectiveness of 
antiviral use on outcomes of public health importance during the 2009–10 influenza 
pandemic. Members of the PRIDE research consortium are listed in appendix pp 1–6.
The initial identification of potential data contributors was done on the basis of a systematic 
search of 11 databases (date of last search April 19, 2012) for observational studies (case 
series, case-control, and cohort studies) and randomised controlled trials done between 
March 1, 2009 (Mexico), or April 1, 2009 (rest of the world), until the WHO declaration of 
the end of the pandemic (Aug 10, 2010), assessing the association between neuraminidase 
inhibitor treatment and clinical outcomes (mortality, influenza-related pneumonia, admission 
to critical care, length of stay in hospital and admission to hospital). We searched Ovid 
Medline (reports from 1996 onwards) and Embase (1980 onwards) using a comprehensive 
search strategy. We also searched CINAHL, CAB Abstracts, ISI Web of Science, PubMed, 
UK PubMed Central, Scopus, WHO regional indexes, LILAC, and J-STAGE databases 
using Boolean logic and core search terms relating to pandemic influenza (including 
influenza A virus OR H1N1 subtype OR swine origin influenza AH1N1 virus) AND 
exposure of interest—ie, antiviral drugs (including neuraminidase inhibitors OR oseltamivir 
OR zanamivir OR peramivir) AND clinical outcome measures (including pneumonia, or 
critical care/intensive care, or mortality). We identified further studies from reference lists of 
relevant articles and through contact with subject area experts (via JSN-V-T). All search 
results were limited to human beings with no language restrictions. Our detailed search 
strategy is reported elsewhere.17
On the basis of this search, we contacted 401 potential data contributors, identified during 
the conduct of our previously reported systematic review;17 these potential contributors 
included several corresponding authors from different papers but potentially related to the 
same source dataset, as an all-inclusive approach. We recruited additional centres through 
our network of global collaborators, publicity at conferences attended, and by word of 
mouth. Centres fulfilling the minimum dataset requirement (appendix pp 7–8) were eligible 
for inclusion. We requested data for both laboratory confirmed and clinically diagnosed 
pandemic influenza A H1N1pdm09 cases, but allowed centres to provide individual patient 
data extending to March 14, 2011 (third pandemic wave cases). Clinically diagnosed cases 
that could not be confirmed by virology were diagnosed on the basis of clinical signs and 
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symptoms that, in the opinion of the attending physician, were judged to be representative of 
influenza-like illness, in the absence of any other more likely diagnosis. We deliberately 
accepted diagnoses made on clinical judgment rather than specifying a set of clinical 
criteria, since case definitions ofinfluenza-like illness vary within and between countries. 
This study was granted exemption from full ethical review by the University of Nottingham 
Medical School Research Ethics Committee, provided that each contributing centre held its 
own institutional review board approval for data collection and sharing.
Data standardisation, exposures, outcomes, and covariates
A common data dictionary was developed and individual datasets standardised according to 
these definitions (appendix pp 9–15) before pooling for analysis.
The primary outcome variable was mortality, defined as death occurring during admission to 
hospital or individual study follow-up period for the generalised linear mixed regression 
models and as death occurring within 30 days of illness onset in the Cox regression models. 
Use of neuraminidase inhibitors (exposure) was defined and compared as follows: 
neuraminidase inhibitor treatment (irrespective of timing) versus none; early neuraminidase 
inhibitor treatment (starting treatment ≤2 days after symptom onset) versus later (initiation 
>2 days after symptom onset); early neuraminidase inhibitor treatment versus none; and 
later neuraminidase inhibitor treatment versus none. Additionally, we created a continuous 
exposure variable, representing time (in days) between symptom onset and treatment 
initiation (0 meaning treatment commenced on day of symptom onset). Covariates in the 
final multivariable models were “inpatient treatment with oral or intravenous antibiotics” 
and “inpatient treatment with systemic corticosteroids” prescribed during the admission to 
hospital for influenza along with treatment propensity scores. We were unable to adjust for 
dose or duration of such treatments because of the scarce availability of these data across the 
individual datasets.
Propensity scoring
We calculated propensity scores for the likelihood of neuraminidase inhibitor treatment for 
each patient within individual datasets using multivariable logistic regression for binary 
treatment variables and generalised propensity score estimation for the continuous time to 
treatment variable as described by Hirano and Imbens.19 For each separate study dataset we 
calculated propensity scores (likelihood of treatment) for each of the four main exposure 
measures: neuraminidase inhibitor at any time (yes or no), early versus late neuraminidase 
inhibitor, early versus no neuraminidase inhibitor, and later (>2 days) versus no 
neuraminidase inhibitor. Covariates were then included as follows, irrespective of 
significance: age, sex, comorbidity (yes or no), a proxy indicator of severe disease (yes or 
no), which were, in order of preference, severe respiratory distress; shortness of breath; 
unweighted symptom score; or, if none of these indicators were available, we used one of 
the following measures of severity: AVPU (alert, voice, pain, unresponsive) mental status 
examination score, Glasgow Coma Scale score, Sequential Organ Failure Assessment score, 
or CURB-65 (confusion, urea, respiratory rate, blood pressure, age ≥65 years) pneumonia 
severity scores, if these were available, entered as a continuous variable. We added the 
following variables when available to create an extended model, using a parsimonious 
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approach that retained only significant covariates in the final model: obesity, smoking, 
pregnancy, asthma, chronic obstructive pulmonary disease, lung disease, heart disease, 
immunosuppression, neurological disease, renal disease, and diabetes. We rejected variables 
with more than 25% missing data. Some variables used for the propensity score calculation, 
such as comorbidity (binary) and illness severity at presentation (binary), were derived at 
individual study level only and were not appropriate for inclusion in the pooled dataset 
analysis because of the heterogeneity in definition of these variables between studies.
The appropriateness of the propensity derivation models was assessed graphically by 
comparing the distribution of estimated propensity scores across treatment groups for each 
individual dataset.20 Propensity scores were then categorised into quintiles for each 
individual dataset.
Statistical analysis
We used a generalised linear mixed model to account for clustering of effects by study using 
the xtmelogit command in Stata (version 12). We included “study” as a random intercept to 
account for differences in baseline crude mortality rate at each site. We adjusted the model 
for treatment propensity, inpatient antibiotics, and systemic corticosteroids. We included 
missing data in covariates as a separate dummy category. The overall analysis included 
patients of all ages with laboratory or clinically diagnosed influenza A H1N1pdm09. We did 
prespecified stratified analyses for adults and children (<16 years), pregnant women 
(irrespective of age), laboratory confirmed influenza A H1N1pdm09 cases, and patients 
admitted to critical care units. Additionally, for a subset of our sample for whom exact onset 
and treatment initiation times were available, we investigated the association between time 
to initiation of antiviral treatment and mortality within 30 days of illness onset using a time-
dependent Cox regression shared frailty model (to account for clustering by study) adjusted 
for propensity score and inpatient treatment with antibiotics or systemic corticosteroids. 
Antiviral treatment was modelled as a time-dependent covariate to overcome immortal time 
bias (ie, survivor bias). Results from the generalised linear mixed model are expressed as 
relative risks of mortality using odds ratios (ORs) and hazard ratios (HRs) for the Cox 
regression analysis with 95% CIs. We used Stata (version 12) for all analyses.
The protocol21 for this study was registered with the PROSPERO register of systematic 
reviews, number CRD42011001273.
Role of the funding source
The funder of the study had no role in the study design, data collection, data analysis, data 
interpretation, or writing of the report. The funder has not and will never have access to the 
data. Each collaborator had access to the raw data from his or her centre. SGM, SV, PRM, 
JL-B, and JSN-V-T had access to the pooled dataset. The corresponding author (JSN-V-T) 
had full access to all the data in the study and the final responsibility for the decision to 
submit for publication.
Muthuri et al. Page 5
Lancet Respir Med. Author manuscript; available in PMC 2019 July 18.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Results
We received replies from 128 (32%) of 401 centres contacted; of these 77 (60%) confirmed 
willingness to participate and the remainder declined (36 [28%] had no data; three [2%] 
agreed initially but later withdrew because of lack of capacity for data extraction, 
institutional review board restrictions preventing sharing of individual participant data, or 
failure to obtain government approval for data sharing; 12 [9%] had agreed in principle, but 
were unable to share data within project timescales). No data were requested from nor 
provided by pharmaceutical companies. After exclusion of duplicate responses (same source 
dataset), and addition of three further datasets provided through informal contact with 
domain experts, 80 research groups from 38 countries in six WHO regions contributed 
anonymised data for 168 117 patients, of whom 24416 had laboratory results indicative of 
noninfluenza A H1N1 disease. Among the remaining 143 701 laboratory confirmed or 
clinically diagnosed (without standard study-wide case definition) influenza A H1N1pdm09 
cases, 106 138 were outpatients and 2593 had missing information for hospital admission. 
The remaining 34 970 inpatients were eligible for inclusion (figure 1).
Of the 34 970 inpatients eligible for inclusion, 2095 (6%) had missing information for 
mortality status, and 3584 (10%) for exposure to neuraminidase inhibitors; 57 (<1%) were 
unsuitable for inclusion for other reasons (figure 1). Ultimately, we included 29 234 records 
from 78 studies (two studies provided only outpatient data and were excluded from analysis) 
of patients admitted to hospital between Jan 2, 2009, and March 14, 2011: 25 001 (86%) 
laboratory confirmed; 9218 (32%) children; and 1600 (5%) aged 65 years or older. 
Appendix p 16 show the incidence of cases by month. Full characteristics of the pooled 
dataset are listed in table 1 with absolute risks of mortality for various exposure categories 
and subgroups summarised in appendix p 16. Baseline characteristics of each constituent 
dataset are presented in appendix pp 17–21.
Patients without neuraminidase inhibitor treatment data and therefore excluded from 
analysis were more likely to be older, to have presented to hospital later, less likely to have a 
laboratory confirmed diagnosis, and more likely to be treated with antibiotics than were 
patients included in the analysis (appendix pp 26–27). However, they were less likely to be 
smokers, obese, or to have an underlying comorbidity. Additionally, their hospital stay was 
shorter, and they were less likely to have severe outcomes (admission to critical care unit or 
death), or influenza-related pneumonia (appendix pp 26–27).
After adjustment for propensity score and corticosteroid and antibiotic treatment, the 
likelihood of mortality in patients treated with a neuraminidase inhibitor was 0·81 (95% CI 
0·70–0·93), compared with no treatment (table 2). The OR did not change substantially 
when only laboratory confirmed cases were included (adjusted OR 0·82 [95% CI 0·70–
0·95]). Similarly, we identified significant associations with a reduced mortality risk in 
adults, pregnant women, and critically ill adult patients (table 2). However, there was no 
significant association between neuraminidase inhibitor treatment and mortality in children 
aged 0–15 years (table 2). Post-hoc analyses restricted to children up to 1 year of age and up 
to 5 years of age did not change this finding (appendix p 27).
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Early neuraminidase inhibitor treatment compared with later treatment initiation was 
associated with an overall significant reduction in mortality risk (adjusted OR 0·48 [95% CI 
0·41–0·56]; table 3). The ORs remained essentially unchanged when only laboratory 
confirmed cases were considered, but risk reduction was higher in pregnant women (table 3). 
Notably, there was again no significant association between early treatment and mortality in 
children after adjustment (table 3).
Neuraminidase inhibitor treatment within 2 days of symptom onset compared with none was 
also associated with a significant reduction in mortality in all patients (adjusted OR 0·50 
[95% CI 0·37–0·67]; table 3), with significant risk reductions also noted among laboratory 
confirmed cases, adults, pregnant women, and adult patients admitted to critical care (table 
3). However, there was no significant association with a lower mortality risk in children aged 
0–15 years (table 3).
With regard to neuraminidase inhibitor treatment started more than 2 days after symptom 
onset compared with none, we identified no significant association with mortality in all 
patients (adjusted OR 1·20 [95% CI 0·93–1·54]), nor in laboratory confirmed cases, adults, 
pregnant women, or children (table 4). However, we noted an associated mortality risk 
reduction of about a third (adjusted OR 0·65 [95% CI 0·46–0·93]) in adult patients admitted 
to critical care.
Information about exact timing of neuraminidase inhibitor treatment from symptom onset 
was available for 65% (12284 of 18803) of those receiving such treatment. After taking into 
account clustering by study, propensity score quintiles, and inhospital treatment with 
antibiotics or systemic corticosteroids, when antiviral use was modelled as a time-dependent 
covariate to overcome potential immortal time bias (ie, survivor bias), neuraminidase 
inhibitor treatment was significantly associated with decreased hazard rate of mortality over 
a 30-day follow-up period (adjusted HR 0·51 [95% CI 0·45–0·58], p<0·0001) as compared 
with no antiviral treatment. When only treated cases were included, there was an increase in 
the hazard with each day’s delay in initiation of treatment up to day 5 as compared with 
treatment initiated within 2 days of symptom onset (adjusted HR 1·23 [95% CI 1·18–1·28], 
p<0·0001 for the increasing HR with each day’s delay). The unadjusted and adjusted 
survival curves comparing survival by time to treatment initiation are shown in figure 2 and 
appendix pp 28–29.
Discussion
Our results show that neuraminidase inhibitor treatment was associated with reduced 
mortality in adult patients admitted to hospital with influenza A H1N1pdm09 virus 
infection. Neuraminidase inhibitor treatment of influenza A H1N1pdm09 at any stage of 
illness compared with none revealed an associated reduction in the likelihood of mortality 
(table 2). We identified an associated likelihood of lower mortality when comparing early 
versus later initiation of treatment and when comparing early treatment with none (table 3, 
panel). Although we included 4233 patients (14%) without laboratory confirmed influenza A 
H1N1pdm09, restriction to laboratory-confirmed cases produced near identical estimates, 
suggesting that the data are not confounded by misclassification bias attributable to other 
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causes (tables 2, 3). Additionally, we noted much the same findings in adults, pregnant 
women, and adult patients needing admission to critical care. The finding regarding critical 
care suggests that neuraminidase inhibitors were associated with mortality reduction across 
the spectrum of severity in adult patients admitted to hospital with influenza A H1N1pdm09. 
These findings accord closely with previous studies16,17 but have increased precision and 
reduced estimates of effectiveness consistent with more complete adjustment for 
confounders and treatment propensity. They are also consistent with ecological data.23-25
We were consistently unable to show any association of neuraminidase inhibitor treatment 
with mortality reduction in children. Possible explanations include lower case fatality 
proportion in paediatric patients (thus reduced statistical power),26,27 higher influenza A 
H1N1pdm09 viral load in children28 than adults leading to reduced drug effectiveness, 
suboptimum dosing in very young children,29 secondary bacterial infections (eg, meticillin-
resistant Staphylococcus aureus), confounding by indication30 (children might have been 
more likely to have had antivirals prescribed if they had more severe disease or if they failed 
to respond to other treatments), or a combination of these factors. Since it has been 
suggested that younger children might be admitted with milder disease compared with older 
children and adults (precautionary physician behaviour), that the pharmacokinetics and 
pharmacology of oseltamivir might be different in very young children,29 and that influenza 
pathogenesis might differ by age,30 we did post-hoc sensitivity analyses separately in 
children up to 1 year of age and up to 5 years of age, but our findings did not change 
(appendix p 27). However, we note that these results contrast with those of Louie and 
colleagues,32 who recently showed a two-thirds reduction in mortality among children 
treated with neuraminidase inhibitors admitted to hospital with influenza (OR 0·36 [95% CI 
0·16–0·83]).
The finding that no treatment was better than late treatment is probably explained by 
confounding due to illness severity at the point of treatment initiation (ie, confounding by 
indication). Untreated patients probably had milder disease and patients treated later in the 
course of their illness might have had delays in hospital admission, delays in diagnosis after 
admission, or delays in being considered for neuraminidase inhibitor treatment (treatment 
only started once their condition deteriorated), or combinations of these factors. We 
advocate early consideration of a diagnosis of influenza in patients admitted to hospital with 
respiratory infection during periods of known influenza activity, and early instigation of 
neuraminidase inhibitor treatment based on rapid laboratory confirmation or clinical 
suspicion.
Our analyses examining the effect of later treatment versus none are especially relevant to 
the continued clinical debate about the value of delayed therapy. Combining all subgroups of 
patients, we did not identify any protective association with treatment delayed more than 2 
days after symptom onset (table 4). This finding could be explained by confounding by 
indication. However, we noted that in adult patients admitted to critical care, delayed 
treatment was associated with reduced likelihood of mortality compared with no treatment 
(table 4), suggesting that delayed therapy might still be worthwhile in severely ill patients; 
this finding is plausible since, within this subgroup, treated and untreated patients (who all 
needed admission to critical care) are likely to have been more balanced in terms of illness 
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severity thereby overcoming confounding by this factor to some extent. Additionally, some 
patients admitted to critical care might have had prolonged influenza A H1N1pdm09 virus 
replication in the lower respiratory tract, which might benefit from later initiation of 
neuraminidase inhibitor treatment. To gain further understanding about overall timing-
dependent benefit, we modelled time to start of antiviral treatment using a time-dependent 
Cox regression model, which showed a significant detrimental survival benefit associated 
with delay in treatment beyond 2 days after symptom onset (p<0·0001), albeit with 
overlapping 95% CIs when time to treatment was modelled as a categorical variable; the 
latter finding suggests that potential differences in treatment benefit between starting on day 
3 after symptom onset through to more than 5 days after symptom onset cannot be further 
clarified through our data. This finding could seem to conflict with the findings in table 4 
comparing later neuraminidase inhibitor treatment to no neuraminidase inhibitor treatment 
but is not surprising, because by comparing only treated patients in figure 2, we possibly 
eliminated some of the confounding due to indication, which allowed us to identify the 
potential survival benefits conferred by later treatment, albeit detrimental in proportion to 
treatment delay.
One of the strengths of this study is the very large number of patients from geographically 
diverse clinical centres and source populations. We made exhaustive efforts to identify 
suitable datasets from around the world, but nevertheless cannot comment on the extent to 
which bias might have been introduced by failing to include centres that did not respond (we 
cannot say if they had suitable data or not), or that declined to share data; in a worst case 
scenario, it is possible that less than 20% of potential sites contributed to this analysis. 
Furthermore, comparatively few cases were from the WHO African (0·1%) and South-East 
Asia (0·7%) regions, which might limit the extent to which our findings can be generalised.
A clear limitation of our study is that we were unable to adjust specifically for disease 
severity in our multilevel models because of the heterogeneity of severity measures used 
across individual datasets. However, we made every effort to include relevant data including 
severity measures, within each propensity score, but there is still likely to be some residual 
confounding, particularly due to illness severity at presentation. Likewise, we attempted to 
control for study-level biases, such as treatment policies, and healthcare seeking behaviour, 
using multilevel models but there might be residual confounding. A further limitation of our 
dataset is that 10% of the patients had missing data for exposure to neuraminidase inhibitors 
and were excluded from the analysis; the characteristics of these patients are compared with 
those with data for neuraminidase inhibitor exposure in appendix pp 26–27; these patients 
were more likely to be older, to have presented to hospital later, less likely to have a 
laboratory confirmed diagnosis, and more likely to be treated with antibiotics.
The decision to adjust for treatment with antibiotics and corticosteroids was taken after 
consultation with clinical colleagues within the PRIDE study collaboration. This decision 
results from widespread clinical practice to treat patients admitted to hospital with 
respiratory illness with corticosteroids and antibiotics. There is particular uncertainty about 
the possible effect of corticosteroids on the course of severe influenza infection.33,34 
Therefore, it was necessary to separate out the possible effects of antivirals from these other 
commonly used treatments. We did not do specific analyses to establish the potential effect 
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of antibiotic or corticosteroid use on mortality, but recognise that these factors both warrant 
further research. Although we were able to adjust for inpatient antibiotics and systemic 
corticosteroid use, we were unable to adjust for pandemic H1N1 vaccination since 35% 
(8284 of 23633) of our case series were admitted to hospital before the first availability of 
vaccine in October, 2009, and 71% (10 967 of 15 349) of data for vaccination status were 
missing among those admitted after that juncture; however, the available data suggest uptake 
was no higher than 8% during the study period.
This meta-analysis of individual patient data offers the most rigorous assessment of 
mortality benefits of neuraminidase inhibitor treatment during the 2009–10 pandemic that is 
likely to be possible using retrospective observational data. The greatest likelihood of 
reduced mortality seems to be attributable to treatment started within 2 days of symptom 
onset. These data offer evidence of the effectiveness of neuraminidase inhibitors during the 
2009–10 pandemic and are superior to extrapolations from earlier data on seasonal 
influenza; they could retrospectively vindicate prepandemic neuraminidase inhibitor 
antiviral stockpiling decisions made by governments worldwide. Treatment guidance 
policies should increase emphasis on early empirical neuraminidase inhibitor treatment of 
adult patients admitted to hospital after presenting with proven or clinically suspected 
influenza A H1N1pdm09 virus infection. However, most adult patients with suspected or 
confirmed influenza are not admitted to hospital within 48 h of illness onset. Therefore, the 
implications of these findings, although based on patients admitted to hospital with influenza 
A H1N1pdm09, encourage early initiation of neuraminidase inhibitor treatment in 
outpatients who are appreciably unwell with suspected or confirmed influenza, or at 
increased risk of complications, including those with influenza A H3N2 or influenza B. 
Further studies are needed in children to confirm the adequacy of present dose regimens and 
duration of therapy in terms of clinical efficacy.
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Panel: Research in context
Systematic review
Two systematic reviews and meta-analyses have examined the effectiveness of 
neuraminidase inhibitors in reducing mortality due to influenza. Hsu and colleagues16 
considered reported observational data, mainly for seasonal influenza, and concluded that 
oral oseltamivir might reduce mortality (odds ratio [OR] 0·23 [95% CI0·13–0·43]). In our 
own systematic review, we included only reported data from the 2009–10 influenza A 
H1N1 pandemic (all observational) and showed that early neuraminidase inhibitor 
treatment versus none reduced mortality by two thirds (OR 0·35 [95% CI 0·18–0·71]).17 
We applied search terms relating to pandemic influenza (including “Influenza A Virus” 
OR ”H1N1 Subtype” OR “swine origin influenza AH1N1 virus”), AND exposure of 
interest—ie, antiviral drugs (including “neuraminidase inhibitors” OR “oseltamivir” OR 
“zanamivir” OR “peramivir”) AND clinical outcome measures (including “pneumonia”, 
“critical or intensive care”, “mortality”) to 11 databases (search range from Jan 1, 2009, 
to Aug 10, 2010; last search on April 19, 2012) without imposing language restrictions. 
Importantly, both studies acknowledged limitations such as the heterogeneity of studies 
included and inadequate adjustment for potential confounding. Moreover, neither was 
able to adjust for the likelihood of a patient receiving antiviral treatment (propensity)—a 
crucial consideration when antiviral drugs might have been prioritised towards the sickest 
patients.
Interpretation
By using a meta-analysis of individual patient data, which permits a uniform approach to 
potential confounding and adjustment for treatment propensity, and through the assembly 
of a very large international dataset, our study adds substantially to the evidence that 
neuraminidase inhibitors administered to adults admitted to hospital with influenza A 
H1N1pdm09 reduced mortality, especially when started promptly. Since placebo-
controlled randomised controlled trials of neuraminidase inhibitors are not ethically 
feasible during a pandemic, the evidence we have assembled is likely to be the best that 
will be available. The US Centers for Disease Control and Prevention recommend 
neuraminidase inhibitor treatment as early as possible for any patient with confirmed or 
suspected influenza who is hospitalised; has severe, complicated or progressive illness; or 
is at higher risk for influenza complications.22 Neuraminidase inhibitors are also widely 
prescribed in Japan, but elsewhere their use is far less common. Although a similar treat-
all policy existed in the UK in 2009, uptake of neuraminidase inhibitors inpatients 
admitted to hospital with influenza A H1N1pdm09 virus was low.15 We advocate early 
instigation of neuraminidase inhibitor treatment in adults admitted to hospital with 
suspected or proven influenza infection.
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Figure 1: Study flow diagram
*47 overlapping data; one onset of illness before March 1, 2009 (Mexico); nine missing data 
for key variables.
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Figure 2: Survival by time to treatment
HR=hazard ratio. NAI=neuraminidase inhibitor. *Cox regression shared frailty model 
(adjusted for treatment propensity and in hospital steroid or antibiotic use).
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